𝔖 Bobbio Scriptorium

✦ LIBER ✦

PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

✍ Scribed by S.C. Humphreys; E.H. Elbasha; S.A. Ferrante; M. Lion; C. O'Regan

Book ID: 119312721
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 71 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.08.767

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIN50 The Clinical Efficacy and Cost-Eff

PIN50 The Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination with Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis from the Perspective of the Scottish National Health Service (NHS)

✍ E. Nikoglou; S. Humphreys; A. El khoury; S.A. Ferrante; C. O' Regan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PGI18 COST-EFFECTIVENESS ANALYSIS OF TRE

PGI18 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPE I CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

✍ FMR Barros; H Cheinquer; LG Borges; E Santos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Prediction of nonSVR to therapy with peg

Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment

✍ E. Lukasiewicz; M. Gorfine; L. S. Freedman; J.-M. Pawlotsky; S. W. Schalm; C. Fe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

Clinical trial: comparison of weekly onc

Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C

✍ G. SEBASTIANI; A. FERRARI; S. BOCCATO; R. PISTIS; A. ALBERTI 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB